NASDAQ:MIST - Milestone Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.86 +0.22 (+1.12 %) (As of 05/26/2019 04:00 PM ET)Previous Close$19.86Today's Range$19.62 - $20.8052-Week Range$15.09 - $20.80Volume11,633 shsAverage Volume94,555 shsMarket Capitalization$469.63 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada. Receive MIST News and Ratings via Email Sign-up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MIST Previous Symbol CUSIPN/A CIKN/A Webhttp://www.milestonepharma.com/ Phone514-336-0444Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees20 Outstanding Shares23,647,000Market Cap$469.63 million Next Earnings DateN/A OptionableNot Optionable Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions What is Milestone Pharmaceuticals' stock symbol? Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST." Has Milestone Pharmaceuticals been receiving favorable news coverage? Media coverage about MIST stock has trended somewhat negative this week, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Milestone Pharmaceuticals earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of Milestone Pharmaceuticals' key competitors? Some companies that are related to Milestone Pharmaceuticals include Xencor (XNCR), Tricida (TCDA), Pacira Biosciences (PCRX), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Nabriva Therapeutics (NBRV), Zogenix (ZGNX), Prestige Consumer Healthcare (PBH), Zai Lab (ZLAB), Madrigal Pharmaceuticals (MDGL), Innoviva (INVA), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Cambrex (CBM) and Gossamer Bio (GOSS). What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Intuitive Surgical (ISRG), Aqua Metals (AQMS), Applied Therapeutics (APLT), Amarin (AMRN), Amedisys (AMED), Allogene Therapeutics (ALLO), Albireo Pharma (ALBO), Aeglea Bio Therapeutics (AGLE), ADMA Biologics (ADMA) and Axon Enterprise (AAXN). Who are Milestone Pharmaceuticals' key executives? Milestone Pharmaceuticals' management team includes the folowing people: Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 51)Dr. Philippe Douville, Founder & Chief Scientific Officer (Age 57)Mr. Timothy L. Maness, VP of Fin. (Age 59)Dr. Francis Plat, Chief Medical Officer (Age 61)Mr. Lorenz Muller, Chief Commercial Officer (Age 55) When did Milestone Pharmaceuticals IPO? (MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. When does the company's quiet period expire? Milestone Pharmaceuticals' quiet period expires on Tuesday, June 18th. Milestone Pharmaceuticals had issued 5,500,000 shares in its initial public offering on May 9th. The total size of the offering was $82,500,000 based on an initial share price of $15.00. During the company's quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Milestone Pharmaceuticals' stock price today? One share of MIST stock can currently be purchased for approximately $19.86. How big of a company is Milestone Pharmaceuticals? Milestone Pharmaceuticals has a market capitalization of $469.63 million. Milestone Pharmaceuticals employs 20 workers across the globe. What is Milestone Pharmaceuticals' official website? The official website for Milestone Pharmaceuticals is http://www.milestonepharma.com/. How can I contact Milestone Pharmaceuticals? Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected] MarketBeat Community Rating for Milestone Pharmaceuticals (NASDAQ MIST)Community Ranking: NaN out of 5 ()Outperform Votes: 0 (Vote Outperform)Underperform Votes: 0 (Vote Underperform)Total Votes: 0MarketBeat's community ratings are surveys of what our community members think about Milestone Pharmaceuticals and other stocks. Vote "Outperform" if you believe MIST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MIST will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: How mutual funds make money Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.